Drug Profile
AFI 002
Alternative Names: AFI-002Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Altus Formulation Inc
- Developer Altus Formulation Inc; Unknown
- Class Behavioural disorder therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in Canada (PO, Controlled release)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in USA (PO, Controlled release)
- 29 Jul 2016 Preclinical trials in Attention-deficit hyperactivity disorder in Canada (PO)